• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

    8/26/24 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email

    Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network

    McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures.

    McKesson will purchase its controlling interest for approximately $2.49 billion in cash, which will represent approximately 70% ownership. Following completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson's US Pharmaceutical segment. The transaction is subject to customary closing conditions, including necessary regulatory clearances. Following the close of the transaction, FCS, a practice with more than 250 physicians and 280 advanced practice providers, across nearly 100 locations in Florida, will remain independently owned and FCS will join McKesson's The US Oncology Network (The Network), a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes.

    "This milestone marks an important step forward in our efforts to advance community-based oncology care," said Brian Tyler, chief executive officer, McKesson. "By growing our Oncology platform, we will bring advanced treatments and improved care experiences to patients, while also reducing the overall cost of care. FCS and Core Ventures' expertise and patient-first approach align with our commitment to accelerating clinical development, improving patient outcomes, and expanding access to quality cancer care in the community. We are also pleased to welcome Florida Cancer Specialists & Research Institute to The US Oncology Network, reinforcing our dedication to empowering community-based providers to independently thrive in today's rapidly evolving healthcare landscape."

    FCS has provided exceptional care to cancer patients for over 40 years. During that time, services have grown to include clinical trials, diagnostic imaging, medical oncology and chemotherapy infusion, integrative therapy, molecular and pathology lab services, radiation oncology, next-generation sequencing, medically integrated dispensing, and data services. FCS currently conducts clinical trials through Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials. By joining The Network, FCS will have access to McKesson's differentiated Oncology platform, including best-in-class oncology care products and services.

    "Above all else, our patients are the true beneficiaries of this transaction, as we seek to drive meaningful outcomes and deliver sustained value with every interaction. Through the power of our combined operational expertise, we can bolster community oncology's role in increasing access to high-quality, affordable care," said Lucio N. Gordan, MD, president and managing physician, FCS.

    "This is a historic moment for FCS and reflects the evolution of our practice and the forward-thinking of physician leadership, our board, and the entire organization at large," said Nathan H. Walcker, chief executive officer of FCS. "The US Oncology Network and FCS share a mission and we both aim to strengthen patient-centered cancer care in the community to improve outcomes. We are thrilled to partner with McKesson and join The Network, which furthers the joint commitment to bringing the best medicine and innovation for patients into communities across Florida."

    Cautionary Statements

    Except for historical information, statements in this press release regarding McKesson's proposed acquisition and related arrangements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company's most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unable to obtain necessary regulatory approvals; we may not achieve expected outcomes from the transaction; we might be adversely impacted by delays or other difficulties, including related to the transactions described in this press release; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, economic events and other catastrophic events.

    About McKesson

    McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.

    About McKesson Oncology and Specialty Solutions

    It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.

    • McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute.
    • The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
    • Ontada®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care.
    • As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
    • And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240825655340/en/

    Get the next $MCK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Tyler Brian S. gifted 4,000 shares, decreasing direct ownership by 8% to 47,243 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      6/11/25 2:05:11 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Tyler Brian S. sold $13,673,864 worth of shares (19,370 units at $705.93), decreasing direct ownership by 27% to 51,243 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      6/9/25 3:28:44 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP, Chief Strategy & BDO Rodgers Thomas L sold $2,058,912 worth of shares (2,891 units at $712.18), decreasing direct ownership by 53% to 2,544 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      6/2/25 6:40:36 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date

      McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he

      6/26/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson to Host Investor Day on September 23, 2025

      McKesson Corporation (NYSE:MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson's leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company's strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along with the company's slide presentation will be available on McKesson's Investor Relations website at investor.mckesson.com, where you can find a complete listing of upcoming events, including details and updates. About McKesson Corporati

      6/11/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of Core Ventures

      Strengthens Community-Based Oncology Care with Florida Cancer Specialists & Research Institute Core Ventures McKesson Corporation (NYSE:MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities. McKesson acquired an approximate 70% controlling intere

      6/3/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Financials

    Live finance-specific insights

    See more
    • McKesson Corporation Announces First Quarter Fiscal 2026 Earnings Release Date

      McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live and archived audio webcast will be available on McKesson's Investor Relations website. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to he

      6/26/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of Core Ventures

      Strengthens Community-Based Oncology Care with Florida Cancer Specialists & Research Institute Core Ventures McKesson Corporation (NYSE:MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities. McKesson acquired an approximate 70% controlling intere

      6/3/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    See more
    • McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

      Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

      8/26/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

      10/4/23 4:05:00 PM ET
      $KRMD
      $MCK
      Medical/Dental Instruments
      Health Care
      Other Pharmaceuticals
    • Gentherm Announces Dr. Ken Washington as New Independent Director

      NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

      10/2/23 8:00:00 AM ET
      $AMZN
      $F
      $MCK
      $MDT
      Catalog/Specialty Distribution
      Consumer Discretionary
      Auto Manufacturing
      Other Pharmaceuticals

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/13/24 5:09:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      1/25/24 1:48:52 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/10/22 8:27:59 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on McKesson with a new price target

      Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

      12/4/24 7:43:38 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

      11/7/24 6:29:13 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

      9/24/24 8:19:53 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    SEC Filings

    See more
    • SEC Form 144 filed by McKesson Corporation

      144 - MCKESSON CORP (0000927653) (Subject)

      7/11/25 10:43:52 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by McKesson Corporation

      DEFA14A - MCKESSON CORP (0000927653) (Filer)

      7/2/25 4:18:08 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by McKesson Corporation

      DEFA14A - MCKESSON CORP (0000927653) (Filer)

      6/20/25 4:26:12 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care